Microdiversity Predicts Outcome in Children's Kidney Cancer
|
By LabMedica International staff writers Posted on 08 Feb 2015 |

Image: CT Scan of 11-centimeter Wilms' tumor of the right kidney in a 13-month-old patient (Photo courtesy of Wikimedia Commons).
A prognosis for the outcome of Wilms' tumor, the most common type of kidney cancer in children, can be determined by examining the genetic variation in a biopsy specimen as small as one millimeter in diameter.
Investigators at Lund University (Sweden) have termed genetic variation in such minute samples as microvariation or microdiversity. They established the importance of this type of variation by analyzing millimeter sized specimens from 44 cases of Wilms' tumor. All 44 patients had been treated with chemotherapy and while most recovered, a few—whose cancers demonstrated the greatest genetic variation between cells—developed metastases and died. Survival was 100% for patients lacking microdiversity.
Very few markers have been found in childhood kidney cancer that can differentiate between aggressive and less dangerous cancers. "The reason for this is that researchers have been looking for certain characteristics, such as mutations, in a single sample from each patient. However, when there is so much variation between the cells, one sample is not enough to determine the properties of the tumor," said senior author Dr. David Gisselsson, a researcher in clinical genetics at Lund University. "Tumors in children are also genetically unstable, and the greater the variation between the cells, the more malignant the cancer. The microvariation is a much better predictor of the risk of metastasis and death than the presence of individual mutations. This is an entirely new way of assessing how dangerous a tumor is."
The study was published in the January 27, 2015, online edition of the journal Nature Communications.
Related Links:
Lund University
Investigators at Lund University (Sweden) have termed genetic variation in such minute samples as microvariation or microdiversity. They established the importance of this type of variation by analyzing millimeter sized specimens from 44 cases of Wilms' tumor. All 44 patients had been treated with chemotherapy and while most recovered, a few—whose cancers demonstrated the greatest genetic variation between cells—developed metastases and died. Survival was 100% for patients lacking microdiversity.
Very few markers have been found in childhood kidney cancer that can differentiate between aggressive and less dangerous cancers. "The reason for this is that researchers have been looking for certain characteristics, such as mutations, in a single sample from each patient. However, when there is so much variation between the cells, one sample is not enough to determine the properties of the tumor," said senior author Dr. David Gisselsson, a researcher in clinical genetics at Lund University. "Tumors in children are also genetically unstable, and the greater the variation between the cells, the more malignant the cancer. The microvariation is a much better predictor of the risk of metastasis and death than the presence of individual mutations. This is an entirely new way of assessing how dangerous a tumor is."
The study was published in the January 27, 2015, online edition of the journal Nature Communications.
Related Links:
Lund University
Latest Pathology News
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
- Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreMolecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more




.jpg)


